John Taylor, new Idera Pharmaceuticals CEO
September 29, 2022 07:10 AM EDT
Deals

As lead drug flopped and Ab­b­Vie col­lab dis­solved, can­cer biotech re­sorts to buy­ing rare dis­ease com­pa­ny

Amber Tong

Ever since dis­ap­point­ing late-stage da­ta on its can­cer drug tanked Idera Phar­ma­ceu­ti­cals’ stock last year (un­helped by an ill-fat­ed col­lab­o­ra­tion with Ab­b­Vie), ex­ecs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times